Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phage pastilles
- Development stage
- Unknown
- Lead developer
- George Eliava Institute of Bacteriophage, Microbiology and Virology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Phage pastilles (commercially known as Phagovita) are a sustained-release, oral lozenge formulation developed by the George Eliava Institute of Bacteriophage, Microbiology and Virology and Eliava BioPreparations. The formulation combines a broad-spectrum cocktail of lytic bacteriophages (including those from the Pyophage and Intestiphage cocktails, as well as the novel Streptococcus pyogenes-targeting phage vB_SPY_7) with plant-derived active ingredients such as eucalyptus oil or sage oil/extract. Designed to treat infections of the oral cavity and upper respiratory tract, Phagovita provides localized, prolonged antimicrobial activity against key pathogens like Streptococcus spp., Staphylococcus spp., Enterococcus spp., and Escherichia coli, while minimizing disruption to the surrounding healthy microbiome. It is commercially available in Georgia as an alternative or adjunctive therapy to combat multidrug-resistant bacterial infections.
- Brand names
- PhagovitaPhagovita EPhagovita S
- Other names
- PHAGOVITAphage pastillephage-containing pastilles
Beyond the preview
Go deeper on phage pastilles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phage pastilles.